Cistron Biotechnology(CIST)$.30 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Harmon who wrote (2432)	9/9/1999 5:12:00 PM
From: Walter Morton	Read Replies (1) of 2742

Does this make you wonder? The company (Immunex) has risen to prominence in the biotechnology industry largely on the outstanding success of its new Enbrel breakthrough for rheumatoid arthritis. Sales should surpass $380 million this year, as the well-tolerated injectable drug finds greater acceptance in treating chronic inflammatory diseases that affect some 2.5 million in the U.S. Recent clinical data have demonstrated Enbrel's effectiveness in treating early-stage rheumatoid arthritis, which is a potentially much larger market. New studies also indicate that Enbrel may be beneficial in treating congestive heart failure. Enbrel eventually is expected to become a multi-billion dallar drug that generates significant products. The R&D pipeline also includes new treatments for multiple sclerosis, asthma, cancer, AIDS, and other ailments. The shares have speculative appeal for aggressive investors. A TD Waterhouse Investor Services Exclusive form Standard & Poor's

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next